Drugs / ASP0739
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04939701 | Dec 2021 → Jun 2023 | esophageal squamous cell carcinoma, non-small cell lung carcinoma, ovarian cancer | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP0739 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04939701 ↗ |
| Modality | Cell therapy | “ASP0739 (human embryonic kidney cell [HEK293] transfected with a lentiviral vector that is encoding the target antigen NY-ESO-1)” NCT04939701 ↗ |
| Route | Intravenous | “Intravenous (IV)” NCT04939701 ↗ |